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Abstract
Background: Women with a short cervical length in mid-trimester pregnancy have a higher risk of preterm birth
and therefore a higher rate of neonatal mortality and morbidity. Progesterone can potentially decrease the number
of preterm births and lower neonatal mortality and morbidity. Previous studies showed good results of
progesterone in women with either a history of preterm birth or a short cervix. However, it is unknown whether
screening for a short cervix and subsequent treatment in mid trimester pregnancy is effective in low risk women.
Methods/Design: We plan a combined screen and treat study among women with a singleton pregnancy without a
previous preterm birth. In these women, we will measure cervical length at the standard anomaly scan performed
between 18 and 22 weeks. Women with cervical length ≤ 30 mm at two independent measurements will be randomly
allocated to receive either vaginal progesterone tablets or placebo between 22 and 34 weeks. The primary outcome of
this trial is adverse neonatal condition, defined as a composite outcome of neonatal mortality and severe morbidity.
Secondary outcomes are time to delivery, preterm birth rate before 32, 34 and 37 weeks, days of admission in neonatal
intensive care unit, maternal morbidity, maternal admission days for preterm labour and costs. We will assess growth,
physical condition and neurodevelopmental outcome of the children at two years of age.
Discussion: This study will provide evidence for the usefulness and cost-effectiveness of screening for short
cervical length at the 18-22 weeks and subsequent progesterone treatment among low risk women.
Trial registration: Netherlands Trial Register (NTR): NTR207
Background
Spontaneous preterm delivery is the single most important
cause of perinatal mortality in the Western world [1]. It is
known that cervical length measurement at 20 to 24
weeks gestation can identify women at increased risk for
preterm delivery [2,3]. However, an effective treatment
was not available until recently.
A breakthrough in the management of women at
increased risk is the use of progesterone. Two rando-
mized clinical trials demonstrated a reduction in preterm
birth of 50% in women with a previous preterm birth
[4,5]. The number of women who delivered prior to 32
weeks in both studies decreased from 20% to 10%. The
effectiveness of progesterone was also addressed in a
recent meta-analysis [6].
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Relative to women allocated to placebo, those who
received progestational agents (17[alpha]-hydroxyproges-
terone caproate and other forms of progesterone) had
lower rates of preterm delivery (26% versus 36%), corre-
sponding to a number needed to treat to prevent one
premature delivery of 10. In addition, women who had
received progestational agents had lower rates of perina-
tal mortality (14.8% versus 17.1%).
The problem with the use of progesterone at present is
that, based on current evidence, it can only be applied to
women with a history of preterm birth. However, the
large majority of spontaneous preterm delivery occurs in
nulliparous women, and progesterone has not been
assessed in those women [7]. On the other hand, predic-
tion of preterm birth in nulliparous women has been stu-
died widely. Fetal fibronectin, cervical length, upper
genital tract infection, and bacterial vaginosis are predic-
tors of preterm birth and in various combinations,
proved to be stronger predictors, depending on race and
gestational age. At 24 weeks, cervical length below
25 mm was the best predictor of spontaneous preterm
birth at all gestational ages. Of the risk factors evaluated
at 28 and 30 weeks, fetal fibronectin was the only signifi-
cant predictor of spontaneous preterm birth < 32 weeks
[8].
In a European cohort of 47.123 women, the cervix was
15 mm or less in 470. The proportion of preterm delivery
in this group was almost 25%. In a randomised clinical
trial attached to this study, the insertion of a Shirodkar
suture in women with a short cervix did not substantially
reduce the risk of early preterm delivery [9].
In view of the studies mentioned above, two conclusions
can be drawn. First, progesterone is an effective treatment
for women who are at increased risk for preterm birth due
to a previous spontaneous preterm delivery. Second, rou-
tine sonographic measurement of cervical length at 22-24
weeks identifies a group of nulliparous women at
increased risk of early preterm birth.
These two issues generate the hypothesis that the use of
progesterone in women with a short cervical length can
reduce the preterm delivery rate. In August 2007, the first
randomised study on the effectiveness of progesterone in
women with a singleton pregnancy and a short cervical
length without a history of spontaneous preterm birth was
published [4]. Spontaneous delivery before 34 weeks of
gestation was less frequent in the progesterone group than
in the placebo group (19% vs. 34% relative risk, 0.56). Pro-
gesterone was associated with a non-significant reduction
in neonatal morbidity (8.1% vs. 13.8%; relative risk, 0.59,
P = 0.17). There were no serious adverse events associated
with the use of progesterone. The authors concluded that
in women with a short cervix, treatment with progesterone
reduces the rate of spontaneous early preterm delivery.
However, as a significant effect on neonatal outcome was
lacking, additional data are needed. We propose a national
cohort study in which mid trimester cervical length is
measured in 15.000 women, with subsequent randomisa-
tion of women with a decreased cervical length. The costs
and effects of screening and treatment will be assessed,
taking into account different cut-off values of short cervi-
cal length.
Methods/Design
The study is set in the Dutch Obstetric Consortium a
collaboration of obstetric practices in the Netherlands.
Approximately 200 clinics, including university hospitals,
teaching hospitals, non-teaching hospitals, ultrasound
centres and midwifery practices will participate in this
trial.
To conduct this trial we got approval from the Medical
Ethical Committee, Academic Medical Centre, Amster-
dam the Netherlands (MEC AMC 08-374 and 08-328).
The study will be a cohort study with a randomised clini-
cal trial embedded. We will screen a large cohort of
women with low risk singleton pregnancies at 18-22
weeks gestation. Women with a short cervix will then be
randomly allocated to receive either vaginal progesterone
or placebo until 34 weeks.
Procedures, recruitment, randomisation and collection of
baseline data
In the Triple P screening study, we will offer low risk
women with a singleton pregnancy the possibility to
screen for a short cervix. Women < 18 years of age,
women with a previous preterm birth < 34 weeks or
symptoms of threatened preterm labour (uterine contrac-
tions, ruptured membranes), fetal congenital malforma-
tions and cervical or abdominal cerclage in situ will be
excluded.
The cervical length is measured in addition to the stan-
dard anomaly scan at 18-22 weeks gestation, which all
pregnant women are offered in the Netherlands. At the
end of the standard anomaly scan, the measurement will
be performed using a vaginal probe. The bladder of the
participant needs to be empty. The measurement takes
approximately three minutes and the shortest measure-
ment is used. All participating sonographers will be
asked to complete an e-learning module, specifically
designed to learn the cervical length measurement tech-
nique. Subsequently, prior to participation in the study,
each sonographer will be asked to obtain pictures of five
measurements, which will be judged by the project team.
The cut off level for a short cervical length is ≤ 30 mm.
Initially the cut of level was set at ≤ 25 mm. However,
after we had screened 340 women, only 9 patients had a
cervical length ≤ 25 mm at first measurement; a far lower
rate than expected. Based on these findings the cut of level
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was altered to ≤ 30 mm, which corresponded to other
recruiting trials.
When a cervical length ≤ 30 mm is measured, a
second assessment is offered within two weeks.
This second measurement takes place in the same
hospital. When the first measurement is done in an
ultrasound centre, the second measurement takes place
in the nearest hospital and is performed by a trained
sonographer.
If at the second assessment the cervix remains ≤ 30 mm,
women will be invited to participate in the randomised
clinical trial. Women who are eligible for the study but do
not give informed consent, are registered and data on
their pregnancy outcome will be collected. Progesterone
will not be offered to these women.
All eligible women with a singleton pregnancy and cervi-
cal length ≤ 30 mm will be informed shortly about the
clinical trial by the supervising gynaecologist or midwife.
Subsequently, a trained research nurse will inform the
patient in detail. The patient will also receive written infor-
mation about the study from the research nurse. Following
the study information, the woman is given a minimal of
five days time to consider participation in the clinical trial.
In case of participation, informed consent is obtained for
the treat study.
Once informed consent has been given, and patient
data have been entered in a web based database, compu-
terized randomisation will take place.
Intervention
Each study participant will be given a blister pack
labelled “Progesterone Study, “
that will contain either 200-mg capsules of micronized
progesterone (Utrogestan, Besins International Belgium)
or identical-appearing capsules of placebo (Medicaps).
Progesterone use did not show side effects in other
studies, there was no difference observed between
exposed and non exposed infants [10-12].
Study medication will be taken between 22 weeks and
34 weeks gestational age. The capsules will be self-admi-
nistered vaginally by patients on a daily basis. The label
codes indicating progesterone or placebo are only known
in the central pharmacy. These data will be disclosed to
the central office only after data on primary outcome
have been collected. Researchers involved in the follow
up program of the offspring of women participating in
this study will remain blinded for a longer period. For
emergency cases, a closed envelope with the label codes
is available at the study centre. For purpose of the interim
analysis the label codes will become available to the epi-
demiologist involved in the study as A and B. Baseline
demographic, past obstetric and medical history will be
recorded of all women who participate in the randomised
study.
Outcome measures
The primary outcome measure is composite poor neona-
tal outcome (death or severe morbidity). This composite
morbidity rate contains the following variables: severe
Respiratory Distress Syndrome (RDS), Bronchopulmon-
ary Dysplasia (BPD), Periventricular Leucomalacia >
grade 1, Intracerebral Haemorrhage > grade II, Necrotiz-
ing Enterocolitis (NEC) > stage 1, proven sepsis and
death before discharge from the nursery. The primary
outcome measure will be recorded 10 weeks after the
expected term date.
Secondary outcome are time to delivery, preterm birth
rate before 32, 34 and 37 weeks, days of admission in neo-
natal intensive care unit, maternal morbidity, maternal
admission days for preterm labour and costs. Moreover,
growth, physical condition including close examination of
the genital tract, and neuro-developmental outcome of the
child at 24 months (corrected) age will be assessed.
Next to secondary clinical outcome, the cost-effective-
ness of screening for short cervical length (as done in
Triple P screening), and subsequent treatment in case of
a short cervix, will be assessed for several cut-off levels
of cervical length.
Follow up of women and infants
Follow up will be performed in all children. Question-
naires regarding child development will be sent to all par-
ticipating families at the corrected child age of 24 months.
Child outcomes to be measured are; length, weight and
head circumference, medical history and medical con-
sumption, physical examination with extra attention for
the genital tract, neurological examination (including
gross motor functional classification system for children
with cerebral paresis). assessment of the cognitive and
motor development, using the Bayley Scales of Infant
Development, version III.
Child Behavioural Checklist, will be filled out by the
parents to assess behavioural outcome. Ages and stages
questionnaire will be filled out by all parents
Statistical issues
Sample size calculation
We anticipated an adverse neonatal outcome in 14% of the
pregnancies in which the cervical length is < 15 mm, and
in 3% of the pregnancies with a cervical length between 15
mm and 30 mm. As we assumed that 1.7% of the pregnan-
cies would show a cervical length < 15 mm, and 8.3% of
the pregnancies a cervical length between 15 and 30 mm,
the probability of bad neonatal outcome without interven-
tion with progesterone in women with a cervix shorter or
equal to 30 mm will be 5.0%. This percentage was
expected to be reduced to 2.5% after use of progesterone.
Assuming this decrease of the incidence of adverse neona-
tal outcome from 5% to 2.5%, using a two sided test with
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an alpha of 0.05 and a beta of 0.8, 1, 920 women (960 per
arm) were needed in this study. As we expected that 10%
of the women would have a cervix ≤ 30 mm, and with the
assumption that 50% of the eligible women would partici-
pate, we need to screen almost 40, 000 women in the
Triple P screening study. However since the start of the
study, 3.000 women were screened resulting in only
70 patients with a cervical length ≤30 mm at the first mea-
surement; a far lower rate of short cervix than we
expected. Based on these findings, the feasibility of recruit-
ment, the available budget and the example of similar
international trials we have adjusted our protocol and plan
to screen 15.000 women. Based on the current data, we
hypothesize that we will be able to randomize 100 women.
We aim to combine the trial data with that of other
ongoing studies on the subject in an individual patient
data meta analysis. (13).
Data analysis
The results of the randomised clinical trial will be analysed
according to the intention to treat principle. The effective-
ness of progesterone versus placebo will be assessed by
calculating relative risks and 95% confidence intervals.
Time to delivery will be compared using Kaplan-Meier
curves and log-rank tests. We will evaluate whether there
is an interaction between the treatment effect and cervical
length, and between treatment effect and ethnicity.
Economic evaluation
General considerations
The economic analysis will be performed from the societal
perspective. Both costs and outcomes will be discounted
with a discount rate of 5%. The economic analysis of the
trial itself is not of interest. If progesterone is found to
decrease the probability of preterm delivery, then the sav-
ings due to decreased prematurity will always outweigh
the costs of progesterone, which are negligible. The true
economic question to be answered when the trial shows a
beneficial effect is whether the costs of screening (number
needed to screen to detect one woman with a short cervix)
outweigh the cost reduction and health benefits from
treatment with progesterone.
Cost analysis
The study design will enable us to compare the costs
and effects of the following strategies:
I. no screening for cervical length
II. screening for cervical length, and treatment of
women with a short cervical length
For each of these strategies, we will calculate the costs
as well as the effects in terms of poor neonatal outcome
(mortality and severe morbidity, see above). In the cost-
effectiveness analysis, we will then calculate the costs
per prevented case of bad neonatal outcome.
For strategy II, we will assess the screening strategy
using different cut-off levels. We anticipate a stronger
treatment effect in the group with a very short cervix, i.e.
< 15 mm, whereas the treatment effect is likely to be less
strong in the women with a cervix between 15 mm and 30
mm (number need to treat). On the other hand, the num-
ber of women with a short cervix will be smaller when a
cut-off value of 15 mm is used than when the group with
a cervix between 15 and 30 mm is considered to be abnor-
mal (number needed to screen). Thus, the cost-effective-
ness analysis will assess the balance between number
needed to treat and number needed to screen.
For the cost analysis, the process of care is divided
into three cost stages (antenatal stage, delivery/child-
birth, postnatal stage) and three cost categories (direct
medical costs [all costs in the health care sector], direct
non-medical costs [costs outside the health care sector
that are affected by health status or health care] and
indirect costs of the pregnant woman and her partner
[costs of sick leave]). Volumes of health care resource
use are measured prospectively alongside the clinical
study in all participating centres as part of the case
report form.
Cost volumes in the antenatal stage consist of direct
medical costs (e.g. prenatal checkups, costs of screening,
admission due to threatened preterm birth, transport of
patients to perinatal centres, and maternal monitoring
[various lab tests; hospital care]). Costs during childbirth
are dominated by the course of childbirth and type of
delivery. Cost volumes in the postnatal stage consist of
maternal care (hospitalisation etc.) and neonatal care
(admission to neonatal intensive care/neonatology ward,
outpatient visits) and primary care.
Health resource use outside the hospital is recorded
by questionnaires. Direct medical volumes outside the
hospital and direct non-medical volumes are valued
using national reference prices. Indirect costs are quan-
tified but remain unvalued. Study-specific costs are
excluded from analysis.
Discussion
Preterm birth is still a huge problem, with high mortal-
ity and morbidity rates. Progesterone is a safe and
potentially effective treatment for prevention of preterm
birth. Some studies have already proven the use of pro-
gesterone in high risk populations, showing that the
number of preterm births can be reduced.
Unfortunately there is no evidence that progesterone
use decreases neonatal morbidity and mortality. More
research has to be done on the possible effects of pro-
gesterone on the neonatal morbidity and mortality rates.
Simultaneously with the Triple P trial, a number of
other study groups in different countries have set up
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trials to evaluate the effect of progesterone on low risk
pregnancy’s to prevent preterm birth.
Recently one of those study’s showed a reduction of
preterm birth rate with the use of progesterone [13].
If the outcome and data of these studies are pooled a
more conclusive statement can be made on this matter.
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